ArriVent BioPharma, Inc.
$31.39
▲
2.77%
2026-04-21 05:29:01
arrivent.com
NGM: AVBP
Explore ArriVent BioPharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.31 B
Current Price
$31.39
52W High / Low
$30.72 / $16.1
Stock P/E
—
Book Value
$7.24
Dividend Yield
—
ROCE
-57.79%
ROE
-58.88%
Face Value
—
EPS
$-4.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
77
Beta
0.86
Debt / Equity
0.01
Current Ratio
12.83
Quick Ratio
12.83
Forward P/E
-7.8
Price / Sales
—
Enterprise Value
$812.57 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$41.1
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 2. | Canton Strategic Holdings, Inc. | $3.51 | — | $194.33 M | — | -3.9% | -17.99% | $9.08 / $1.05 | $10.72 |
| 3. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 4. | Calidi Biotherapeutics, Inc. | $0.25 | — | $3 M | — | -410.2% | -7.01% | $19.2 / $0.21 | $0.51 |
| 5. | Actuate Therapeutics, Inc. Common stock | $2.62 | — | $54.77 M | — | -270.08% | -5.54% | $11.99 / $1.58 | $0.34 |
| 6. | Madrigal Pharmaceuticals, Inc. | $535 | — | $12.26 B | — | -31.61% | -42.49% | $615 / $265 | $26.39 |
| 7. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -38.82 M | -38.32 M | -33.62 M | -66.77 M | -23.7 M | — |
| Net Profit | -35.54 M | -34.98 M | -31.4 M | -64.39 M | -20.63 M | — |
| EPS in Rs | -0.8 | -0.79 | -0.71 | -1.46 | -0.47 | -0.61 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -177.53 M | -94.31 M | -74.59 M | -36.91 M |
| Net Profit | -166.31 M | -80.49 M | -69.33 M | -36.91 M |
| EPS in Rs | -3.76 | -1.82 | -1.57 | -0.83 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 333.17 M | 274.94 M | 163.1 M | 182.83 M |
| Total Liabilities | 25.95 M | 17.29 M | 316.29 M | 267.94 M |
| Equity | 307.22 M | 257.65 M | -153.19 M | -85.11 M |
| Current Assets | 332.9 M | 226.98 M | 159.97 M | 182.62 M |
| Current Liabilities | 25.95 M | 17.27 M | 11.62 M | 8.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -160.59 M | -70.21 M | -55.84 M | -43.63 M |
| Investing CF | -71.23 M | -192.47 M | 0 M | 0 M |
| Financing CF | 203.06 M | 186.58 M | 42.86 M | 169.72 M |
| Free CF | -160.59 M | -70.21 M | -55.84 M | -43.63 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -106.62% | -16.09% | -87.86% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.